Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant Pharmaceuticals

Executive Summary

Firm will enter into lease for "state-of-the-art, 45,000-square-foot facility that includes a manufacturing plant completed in 2007 specializing in topical formulations" as part of its acquisition of Canadian cosmeceutical maker Laboratoire Dr. Renaud. Valeant Canada Limited will pay approximately $21.69 mil. for the company, which posts annual sales of roughly $10.37 mil., in deal expected to close before year-end. Transaction is expected to be accretive in 2010, according to Dec. 7 release. "This acquisition is part of our continued efforts to build a leading dermatology business by adding respected brand names in our select regions," states Valeant Chairman and CEO J. Michael Pearson. Dr. Renaud "enjoys a high degree of loyalty from esthetic clinics and spas, and we believe that Valeant will gain immediate entrée into the cosmeceutical market in Canada," Pearson adds. Aliso Viejo, Calif.-based Valeant, which markets Kinerase skin care, picked up Private Formula International in October for roughly $69 million, giving it a dominant market presence in Australia (1"The Rose Sheet" Oct. 5, 2009)
Advertisement

Related Content

Valeant nabs Australian skin care
Advertisement
UsernamePublicRestriction

Register

RS016615

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel